RecruitingRecruiting
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)
NCT06917911 · National Cancer Institute (NCI)
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
Phase II Study of Cytarabine + Daunorubicin (7 + 3) + Gemtuzumab Ozogamicin vs. Cytarabine + Daunorubicin (7 + 3) + Venetoclax for the Treatment of Newly Diagnosed Core Binding Factor Acute Myeloid Leukemia (CBF-AML) in Younger Adults: A MyeloMATCH Substudy
About this study
PRIMARY OBJECTIVE:
I. Compare the rates of complete remission (CR) without measurable residual disease (CRMRD-) by multiparameter flow cytometry following induction therapy between the two treatment arms in each cohort separately.
SECONDARY OBJECTIVES:
I. To compare the rates of CR and composite complete remission (CRc) (CR+complete remission with incomplete hematologic recovery \[CRi\]+complete remission with partial hematologic recovery \[CRh\]) between the treatment arms.
II. To compare the overall survival (OS) between the treatment arms. III. To compare the event-free survival (EFS). IV. To compare the cumulative incidence of relapse (CIR). V. To compare the cumulative incidence of death (CID) between the treatment arms.
VI. To compare the rate of early death at 30 days and 60 days between the treatment arms.
VII. To assess the rate and frequency of adverse events between treatment arms. VIII. To evaluate mutant RAS and mutant KIT as predictive biomarkers for CRMRD- rate in CBF AML.
EXPLORATORY OBJECTIVE:
I. To compare MRD (and its clinical implication, e.g., relapse rates) between flow cytometry (FC) and next generation sequencing (NGS)-based (RUNX1::RUNX1T1 or CBFB::MYH11).
CORRELATIVE OBJECTIVES:
I. To evaluate the frequency and clinical impact of variant allele frequency (VAF) of KIT mutation, KIT mutations in different exons (e.g., exon 8 or 17), CD33 expression, additional (secondary) mutations and cytogenetic abnormalities.
II. To evaluate the differences in clinical and molecular outcomes in patients with RUNX1::RUNX1T1 mutated versus CBFB::MYH11 mutated CBF AML.
OUTLINE: Patients are randomized to 1 of 2 regimens.
REGIMEN 1: Patients receive gemtuzumab ozogamicin intravenously (IV) on day 1, 2 or 3 and on day 4, 5, or 6 (NOTE: two doses must be at least 3 days apart), as well as cytarabine IV, continuously, on days 1-7 and daunorubicin IV on days 1-3 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care consolidation/post-remission treatment at the discretion of the treating physician. Patients undergo echocardiography or multigated acquisition (MUGA) scan during screening, as well as bone marrow aspiration and blood sample collection throughout the study.
REGIMEN 2: Patients receive venetoclax orally (PO) once daily (QD) on days 1-11, cytarabine IV, continuously, on days 2-8 and daunorubicin IV on days 2-4 in the absence of disease progression or unacceptable toxicity. Patients then undergo standard of care consolidation/post-remission treatment at the discretion of the treating physician. Patients undergo echocardiography or MUGA scan during screening and bone marrow aspiration, as well as blood sample collection throughout the study.
After completion of study treatment, patients are followed up at relapse and every 3 months for 2 years, then every 6 months until 5 years.
Eligibility criteria
Inclusion Criteria:
* GENERAL MYELOMATCH CRITERIA: Patients must be registered to the Master Screening and Reassessment Protocol, MYELOMATCH, and assigned to this protocol by the MATCHBox Treatment Verification Team
* GENERAL MYELOMATCH CRITERIA: Participants must not have received prior anti-cancer therapy for AML or myelodysplastic syndrome (MDS)
* Note: Hydroxyurea to control the white blood cell count (WBC) and cytarabine up to 1g for urgent cytoreduction is allowed.
* Note: Prior erythroid stimulating agent (ESA) is not considered prior therapy for the purposes of eligibility
* GENERAL MYELOMATCH CRITERIA: Participants must not receive any cytarabine-containing therapy other than up to 1g of cytarabine, which is allowed for urgent cytoreduction. Hydroxyurea, all-trans retinoic acid (ATRA), BCR-ABL directed tyrosine kinase inhibitor, erythropoiesis-stimulating agent, thrombopoietin receptor agonist and lenalidomide is allowed
* Diagnosis of AML with t(8;21)(q22;q22.1)/RUNX1::RUNX1T1 or AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22)/CBFB::MYH11. No FLT3 mutation (these patients should be considered for a FLT3-focused MYELOMATCH study)
* Secondary CBF-AML (e.g., prior pre-leukemic hematologic malignancy or history of chemotherapy/radiation therapy) is allowed.
* No prior AML or MDS-directed therapy except for urgent treatment of leukocytosis with leukapheresis, cytarabine, and hydroxyurea, Prior intrathecal chemotherapy for central nervous system (CNS) involvement of AML is permitted
* Age 18-59 years
* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3
* Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (unless patient has a history of Gilbert syndrome and direct bilirubin is ≤ 1.5 x ULN)
* Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase \[SGOT\])/ alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]) ≤ 3 x upper limit of normal (ULN)
* Glomerular filtration rate (GFR) ≥ 30 mL/min/1.73m\^2
* Not pregnant and not nursing, because this study involves an investigational agent whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown. Therefore, for women of childbearing potential only, a negative urine or serum pregnancy test done ≤ 7 days prior to registration is required
* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
* Participants with CNS disease are eligible for this trial and will be treated according to institutional guidelines with intrathecal chemotherapy for this aspect of their disease
* Patients with known HIV infection on effective anti-retroviral therapy with undetectable viral load within 6 months prior to registration are eligible for this trial
* For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated
* Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load
* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class II or better
* No known medical condition causing an inability to swallow oral formulations of agents
Study design
Enrollment target: 162 participants
Allocation: randomized
Masking: none
Age groups: adult
Timeline
Starts: 2026-09-28
Estimated completion: 2027-11-25
Last updated: 2026-11-04
Interventions
Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationDrug: CytarabineDrug: Daunorubicin HydrochlorideProcedure: Echocardiography TestDrug: Gemtuzumab OzogamicinProcedure: Multigated Acquisition ScanDrug: Venetoclax
Primary outcomes
- • Complete remission without measurable residual disease (CRMRD-) (At end of induction (Up to 28 days))
Sponsor
National Cancer Institute (NCI) · nih
Contacts & investigators
InvestigatorCelalettin Ustun · principal_investigator, Alliance for Clinical Trials in Oncology
All locations (81)
University of Alabama at Birmingham Cancer CenterRecruiting
Birmingham, Alabama, United States
UC San Diego Moores Cancer CenterRecruiting
La Jolla, California, United States
Memorial Hospital WestRecruiting
Pembroke Pines, Florida, United States
Kootenai Health - Coeur d'AleneRecruiting
Coeur d'Alene, Idaho, United States
Kootenai Clinic Cancer Services - Post FallsRecruiting
Post Falls, Idaho, United States
Kootenai Clinic Cancer Services - SandpointRecruiting
Sandpoint, Idaho, United States
Northwestern UniversityRecruiting
Chicago, Illinois, United States
Rush MD Anderson Cancer CenterRecruiting
Chicago, Illinois, United States
University of IllinoisRecruiting
Chicago, Illinois, United States
University of Chicago Comprehensive Cancer CenterRecruiting
Chicago, Illinois, United States
UC Comprehensive Cancer Center at Silver CrossRecruiting
New Lenox, Illinois, United States
University of Chicago Medicine-Orland ParkRecruiting
Orland Park, Illinois, United States
UChicago Medicine Northwest IndianaRecruiting
Crown Point, Indiana, United States
University of Kansas Clinical Research CenterRecruiting
Fairway, Kansas, United States
University of Kansas Cancer CenterRecruiting
Kansas City, Kansas, United States
University of Kansas Hospital-Indian Creek CampusRecruiting
Overland Park, Kansas, United States
University of Kansas Hospital-Westwood Cancer CenterRecruiting
Westwood, Kansas, United States
University of Kentucky/Markey Cancer CenterRecruiting
Lexington, Kentucky, United States
The James Graham Brown Cancer Center at University of LouisvilleRecruiting
Louisville, Kentucky, United States
UofL Health Medical Center NortheastRecruiting
Louisville, Kentucky, United States
Our Lady of the Lake Physician GroupRecruiting
Baton Rouge, Louisiana, United States
Tufts Medical CenterRecruiting
Boston, Massachusetts, United States
Dana-Farber Cancer InstituteRecruiting
Boston, Massachusetts, United States
Trinity Health IHA Medical Group Hematology Oncology - BrightonRecruiting
Brighton, Michigan, United States
Trinity Health IHA Medical Group Hematology Oncology - CantonRecruiting
Canton, Michigan, United States
Trinity Health IHA Medical Group Hematology Oncology - Chelsea HospitalRecruiting
Chelsea, Michigan, United States
Trinity Health Saint Mary Mercy Livonia HospitalRecruiting
Livonia, Michigan, United States
Trinity Health Saint Joseph Mercy Oakland HospitalRecruiting
Pontiac, Michigan, United States
Trinity Health IHA Medical Group Hematology Oncology Ann Arbor CampusRecruiting
Ypsilanti, Michigan, United States
Baptist Memorial Hospital and Cancer Center-Golden TriangleRecruiting
Columbus, Mississippi, United States
Baptist Cancer Center-GrenadaRecruiting
Grenada, Mississippi, United States
Baptist Memorial Hospital and Cancer Center-Union CountyRecruiting
New Albany, Mississippi, United States
Baptist Memorial Hospital and Cancer Center-OxfordRecruiting
Oxford, Mississippi, United States
Baptist Memorial Hospital and Cancer Center-DesotoRecruiting
Southhaven, Mississippi, United States
Siteman Cancer Center at Saint Peters HospitalRecruiting
City of Saint Peters, Missouri, United States
Siteman Cancer Center at West County HospitalRecruiting
Creve Coeur, Missouri, United States
Washington University School of MedicineRecruiting
St Louis, Missouri, United States
Siteman Cancer Center-South CountyRecruiting
St Louis, Missouri, United States
Siteman Cancer Center at Christian HospitalRecruiting
St Louis, Missouri, United States
Community Hospital of AnacondaRecruiting
Anaconda, Montana, United States
Billings Clinic Cancer CenterRecruiting
Billings, Montana, United States
Bozeman Health Deaconess HospitalRecruiting
Bozeman, Montana, United States
Benefis Sletten Cancer InstituteRecruiting
Great Falls, Montana, United States
Logan Health Medical CenterRecruiting
Kalispell, Montana, United States
Community Medical CenterRecruiting
Missoula, Montana, United States
Nebraska Medicine-BellevueRecruiting
Bellevue, Nebraska, United States
Nebraska Medicine-Village PointeRecruiting
Omaha, Nebraska, United States
University of Nebraska Medical CenterRecruiting
Omaha, Nebraska, United States
University of New Mexico Cancer CenterRecruiting
Albuquerque, New Mexico, United States
Roswell Park Cancer InstituteRecruiting
Buffalo, New York, United States
University of RochesterRecruiting
Rochester, New York, United States
State University of New York Upstate Medical UniversityRecruiting
Syracuse, New York, United States
Montefiore Medical Center - Moses CampusRecruiting
The Bronx, New York, United States
Duke University Medical CenterRecruiting
Durham, North Carolina, United States
Ohio State University Comprehensive Cancer CenterRecruiting
Columbus, Ohio, United States
University of Oklahoma Health Sciences CenterRecruiting
Oklahoma City, Oklahoma, United States
Geisinger Medical CenterRecruiting
Danville, Pennsylvania, United States
Geisinger Wyoming Valley/Henry Cancer CenterRecruiting
Wilkes-Barre, Pennsylvania, United States
Rhode Island HospitalRecruiting
Providence, Rhode Island, United States
Prisma Health Cancer Institute - SpartanburgRecruiting
Boiling Springs, South Carolina, United States
Prisma Health Cancer Institute - EasleyRecruiting
Easley, South Carolina, United States
Prisma Health Cancer Institute - ButternutRecruiting
Greenville, South Carolina, United States
Prisma Health Cancer Institute - FarisRecruiting
Greenville, South Carolina, United States
Prisma Health Cancer Institute - EastsideRecruiting
Greenville, South Carolina, United States
Prisma Health Cancer Institute - GreerRecruiting
Greer, South Carolina, United States
Prisma Health Cancer Institute - SenecaRecruiting
Seneca, South Carolina, United States
Baptist Memorial Hospital and Cancer Center-ColliervilleRecruiting
Collierville, Tennessee, United States
Baptist Memorial Hospital and Cancer Center-MemphisRecruiting
Memphis, Tennessee, United States
Huntsman Cancer Institute/University of UtahRecruiting
Salt Lake City, Utah, United States
VCU Massey Comprehensive Cancer CenterRecruiting
Richmond, Virginia, United States
Swedish Cancer Institute-EdmondsRecruiting
Edmonds, Washington, United States
Swedish Cancer Institute-IssaquahRecruiting
Issaquah, Washington, United States
Swedish Medical Center-First HillRecruiting
Seattle, Washington, United States
Gundersen Lutheran Medical CenterRecruiting
La Crosse, Wisconsin, United States
Froedtert Menomonee Falls HospitalRecruiting
Menomonee Falls, Wisconsin, United States
Medical College of WisconsinRecruiting
Milwaukee, Wisconsin, United States
Froedtert and MCW Moorland Reserve Health CenterRecruiting
New Berlin, Wisconsin, United States
Drexel Town Square Health CenterRecruiting
Oak Creek, Wisconsin, United States
Froedtert West Bend Hospital/Kraemer Cancer CenterRecruiting
West Bend, Wisconsin, United States
Centro Comprensivo de Cancer de UPRRecruiting
San Juan, Puerto Rico
San Juan City HospitalRecruiting
San Juan, Puerto Rico